Email this article Detection of autoantibodies to potentially amyloidogenic protein, gamma-synuclein, in the serum of patients with amyotrophic lateral sclerosis and cerebral circulatory disorders
- Authors: Roman A.Y.1,2, Kovrazhkina E.A.3, Razinskaya O.D.3, Kukharsky M.S.1, Maltsev A.V.1, Ovchinnikov R.K.1, Lytkina O.A.1, Smirnov A.P.3, Moskovtsev A.A.4, Borodina Y.V.5, Surguchov A.P.6, Ustyugov A.A.1, Ninkina N.N.1,4, Skvortsova V.I.3
-
Affiliations:
- Institute of Physiologically Active Compounds
- Aix-Marseille Université
- Pirogov Russian National Research Medical University
- Research Institute of General Pathology and Pathophysiology
- Research Center Hospital
- University of Kansas Medical Center
- Issue: Vol 472, No 1 (2017)
- Pages: 64-67
- Section: Biochemistry, Biophysics, and Molecular Biology
- URL: https://journal-vniispk.ru/1607-6729/article/view/211826
- DOI: https://doi.org/10.1134/S1607672917010197
- ID: 211826
Cite item
Open Access
Access granted
Subscription Access
Abstract
In this study, we analyzed serum for the presence of antibodies to gamma-synuclein in patients with amyotrophic lateral sclerosis (ALS) compared to the control group of patients with other neurological diseases and healthy control donors. As a result, antibodies against gamma-synuclein are not an ALS-specific feature and have been identified in patients with ALS as well as in the control group patients. Patients with the impaired cerebral circulation showed increased incidence of autoantibodies to gamma-synuclein, yet the difference lacks statistical representativeness due to limited sample size.
About the authors
A. Yu. Roman
Institute of Physiologically Active Compounds; Aix-Marseille Université
Email: maltsevandro@mail.ru
Russian Federation, Chernogolovka, Moscow oblast, 142432; Inserm
E. A. Kovrazhkina
Pirogov Russian National Research Medical University
Email: maltsevandro@mail.ru
Russian Federation, Moscow, 117997
O. D. Razinskaya
Pirogov Russian National Research Medical University
Email: maltsevandro@mail.ru
Russian Federation, Moscow, 117997
M. S. Kukharsky
Institute of Physiologically Active Compounds
Email: maltsevandro@mail.ru
Russian Federation, Chernogolovka, Moscow oblast, 142432
A. V. Maltsev
Institute of Physiologically Active Compounds
Author for correspondence.
Email: maltsevandro@mail.ru
Russian Federation, Chernogolovka, Moscow oblast, 142432
R. K. Ovchinnikov
Institute of Physiologically Active Compounds
Email: maltsevandro@mail.ru
Russian Federation, Chernogolovka, Moscow oblast, 142432
O. A. Lytkina
Institute of Physiologically Active Compounds
Email: maltsevandro@mail.ru
Russian Federation, Chernogolovka, Moscow oblast, 142432
A. P. Smirnov
Pirogov Russian National Research Medical University
Email: maltsevandro@mail.ru
Russian Federation, Moscow, 117997
A. A. Moskovtsev
Research Institute of General Pathology and Pathophysiology
Email: maltsevandro@mail.ru
Russian Federation, Moscow, 125315
Yu. V. Borodina
Research Center Hospital
Email: maltsevandro@mail.ru
Russian Federation, Chernogolovka, Moscow oblast
A. P. Surguchov
University of Kansas Medical Center
Email: maltsevandro@mail.ru
United States, Kansas
A. A. Ustyugov
Institute of Physiologically Active Compounds
Email: maltsevandro@mail.ru
Russian Federation, Chernogolovka, Moscow oblast, 142432
N. N. Ninkina
Institute of Physiologically Active Compounds; Research Institute of General Pathology and Pathophysiology
Email: maltsevandro@mail.ru
Russian Federation, Chernogolovka, Moscow oblast, 142432; Moscow, 125315
V. I. Skvortsova
Pirogov Russian National Research Medical University
Email: maltsevandro@mail.ru
Russian Federation, Moscow, 117997
Supplementary files
